5 Reasons Your Doctor Won't Prescribe GLP-1 (And How to Change His Mind)
You asked about semaglutide or tirzepatide. Your doctor shut it down. Here's why that happened and what you can do about it — including knowing when he's right.
Men are less likely to ask for help with weight loss. And when they finally do, getting told "just eat less and exercise more" is the fastest way to make sure they never bring it up again. If your doctor dismissed your request for GLP-1 medication, it's worth understanding why — because sometimes the resistance is outdated thinking, and sometimes it's clinically justified.
Here are the five most common reasons doctors say no, what's valid about each one, and what you can say to move the conversation forward.
"You Should Try Diet and Exercise First"
"These medications are a last resort. You need to demonstrate that you've tried lifestyle changes first."
What's valid: Diet and exercise are foundational. GLP-1 medications work best as an adjunct to lifestyle changes, not a replacement. If you haven't made a serious effort at caloric restriction and regular exercise, your doctor has a point.
What's outdated: The idea that medication should only come after years of failed dieting. The American Medical Association and the Obesity Medicine Association both recognize obesity as a chronic disease requiring medical treatment — not a willpower problem. Asking men to fail repeatedly before offering effective medication is not standard of care.
What to say: "I've attempted caloric restriction multiple times and haven't been able to sustain the weight loss. I understand these medications work best with lifestyle changes, and I'm committed to incorporating exercise and nutrition improvement. Can we discuss whether I meet the clinical criteria for pharmacotherapy?"
"Your BMI Isn't High Enough"
"These medications are for people with severe obesity. Your BMI of 28 doesn't qualify."
What's valid: FDA indications require BMI ≥30 (obese), or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). If your BMI is 25 with no comorbidities, you genuinely don't meet current prescribing criteria.
What's outdated: Only looking at BMI without considering comorbidities. A man with BMI 28, elevated blood pressure, prediabetic A1C, and 40-inch waist circumference absolutely qualifies. BMI alone is a crude metric — it doesn't account for visceral fat distribution, which is the real driver of metabolic risk in men.
What to say: "I understand the BMI threshold. Can we look at my full metabolic picture — blood pressure, fasting glucose or A1C, lipid panel, and waist circumference? I believe I may have comorbidities that would qualify me at BMI 27+."
"The Long-Term Safety Data Isn't There Yet"
"These are relatively new medications. We don't know the long-term effects."
What's valid: GLP-1 receptor agonists for weight loss have been widely used for about 5 years. That's substantial but not multi-decade. Some concerns (thyroid C-cell tumors seen in rodent studies, pancreatitis risk, gallbladder events) warrant monitoring. A cautious doctor isn't necessarily wrong to raise this.
What's less valid: GLP-1 medications for diabetes (liraglutide, exenatide) have been used since 2005 — nearly 20 years. The class has extensive safety data. The SELECT trial (17,604 patients, 39 months) showed a 20% reduction in major cardiovascular events. The cardiovascular safety profile is now one of the strongest in any class of weight management medication.
What to say: "I appreciate the caution. Can you help me understand how the cardiovascular risk reduction from the SELECT trial compares to the theoretical long-term risks? Given that obesity itself increases my risk of heart disease, stroke, and type 2 diabetes, what's the risk of NOT treating it pharmacologically?"
"It's Too Expensive and Insurance Won't Cover It"
"These cost over $1,000 a month. I can't prescribe something you can't afford."
What's valid: Brand-name list prices are genuinely high. Not all insurance plans cover GLP-1 medications for weight loss. Prior authorization is common and often denied.
What's changed: The pricing landscape has shifted dramatically. Eli Lilly offers Zepbound at $399/month through LillyDirect for self-pay patients. Novo Nordisk's NovoCare offers Wegovy at $349–$499/month. Compounded options run $146–$300/month. These prices make GLP-1 therapy accessible for many patients who were previously priced out.
What to say: "I've researched the current pricing. Self-pay options through manufacturer programs are now $349–$399/month, and compounded alternatives are even less. Can you write the prescription and let me handle the cost question? I'd also like to try insurance prior authorization — if it's denied, I'll pursue self-pay."
"You Don't Need Medication — You Need Discipline"
"This is a lifestyle problem, not a medical one."
What's valid: Nothing. This is bias, not medicine. The AMA classified obesity as a disease in 2013. The neuroendocrine mechanisms of appetite regulation and weight set points are well-established. Telling a patient with obesity to "just have more discipline" is like telling a patient with depression to "just cheer up" — it's reductive and ignores the biology.
What to do: If this is your doctor's position after a genuine conversation, find a different doctor. A provider who doesn't recognize obesity as a treatable medical condition isn't equipped to manage it. You can find a board-certified obesity medicine specialist through the Obesity Medicine Association's provider directory, or work with a telehealth provider who specializes in weight management.
When Your Doctor Is Right to Say No
To be fair — there are legitimate medical reasons to decline GLP-1 therapy. If you have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, GLP-1 medications are contraindicated. If you have a history of pancreatitis, your doctor should weigh the risk carefully. If you have an active eating disorder, GLP-1 medication may worsen disordered eating patterns. And if your BMI is under 27 with no comorbidities, you genuinely don't meet prescribing criteria.
A good doctor who says no for these reasons is protecting you. The distinction is between a clinically justified refusal and an ideological one.
The Telehealth Alternative
If your primary care doctor won't prescribe GLP-1 medication and you believe you meet the clinical criteria, telehealth providers who specialize in weight management are a legitimate alternative. They're not going around your doctor — they're providing specialty care in a specific domain, the same way you'd see an endocrinologist or cardiologist for their expertise.
Sprout Health
Compounded GLP-1 programs · $250 CPA · Medical consultation included
Sources
- American Medical Association — Resolution 420: Recognition of Obesity as a Disease, 2013
- Obesity Medicine Association — Clinical Practice Guidelines for Medical Management of Obesity, 2024
- Lincoff AM et al. — SELECT trial cardiovascular outcomes. N Engl J Med, 2023
- FDA — Wegovy and Zepbound prescribing information (BMI eligibility criteria)
- Sumithran P et al. — Long-term persistence of hormonal adaptations to weight loss. N Engl J Med, 2011